208 results about "Bile acid" patented technology

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention belongs to the technical field of feed additives, and particularly relates to slow-release fat powder for pigs and a preparation method of the slow-release fat powder. The slow-release fat powder for pigs comprises an intragastric adhesion-slow release layer, a small intestine forepart bile acid response controlled release layer and a small intestine posterior microbe response controlled release layer. The prepared slow-release fat powder for the pigs is good in stability, accurate release of different nutritional ingredients in different parts of gastrointestinal tracts of the pigs can be achieved, and powerful support is provided for sustainable development of the pig raising industry.

The invention provides a water-blocking microcapsule, a fish oil composite hair beautifying ointment and a preparation method, and relates to the technical field of animal health products. The water-blocking microcapsule is a solid particle formed by a core material and a wall material coating the core material; the core material is fish oil emulsion subjected to bile salt emulsification treatment; the wall material sequentially comprises an inner-layer wall material and an outer-layer wall material from inside to outside; the inner-layer wall material is a wall material formed by solidifying alginate; and the outer-layer wall material is a water-blocking wall material which is arranged outside the inner-layer wall material and is made of nanocrystalline cellulose. The water-blocking microcapsule provided by the invention realizes multiple beneficial effects of efficient digestion and absorption of fish oil, improvement of palatability, enhancement of oxidation resistance and stability, fixed-point release of intestinal tracts and the like, provides an innovative technical scheme for development of animal health products, and has wide application prospects and market values.

The invention discloses emblic leafflower fruit polysaccharide with sugar-controlling and lipid-lowering activity as well as a preparation method and application of the emblic leafflower fruit polysaccharide. The polysaccharide is prepared by taking fresh phyllanthus emblica pulp as a raw material through hot water extraction, yeast fermentation, desorption after XAD-16 macroporous resin adsorption, alcohol precipitation, ultrafiltration and DEAE-52 cellulose column purification. The low-molecular-weight gulcomannan is separated from phyllanthus emblica for the first time, and monosaccharide composition of the gulcomannan mainly comprises glucose, mannose and galactose and contains trace rhamnose and xylose. The polysaccharide has sugar-controlling and lipid-lowering active action targets in the whole digestive tract (the upper digestive tract: glycolipid digestion and absorption enzymes alpha-amylase, alpha-glucosidase and pancreatic lipase inhibitory activity, starch hydrolysis delay, bile acid adsorption capacity and cholesterol micelle dissolution inhibition capacity; in the lower digestive tract, the multiplication promoting capacity of glycolipid metabolism-related probiotics) shows extremely high biological activity, and can be applied to food and health care products.

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

The invention relates to a composition for treating large yellow croaker pyramidoniasis as well as a preparation method and application thereof, and belongs to the technical field of aquaculture. The composition comprises the following components: curcumin, bile acid, beta glucan, bacillus subtilis freeze-dried powder, marine red yeast freeze-dried powder, vitamin C, vitamin E and ethylicin. When the feed additive is added into basal feed to feed large yellow croakers infected with the trypanosomiasis, the death rate of sick fishes can be effectively reduced, the polypide loading capacity is remarkably reduced, and pathological injuries of livers and spleens of the large yellow croakers are relieved. In addition, the composition can also improve the non-specific immunity of the fish body, improve the liver function, enhance the antioxidant capacity of the liver, and improve the lipase activity of the intestinal tract at the same time. Therefore, the composition can be used as a medicine or a feed additive for treating the large yellow croaker pyramidoniasis, has the advantages of small dosage and remarkable effect, and provides a new technical approach for solving the problem that the current large yellow croaker pyramidoniasis lacks an effective prevention and control means.

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The invention belongs to the technical field of fermentation and metagen preparations, and particularly relates to application of bifidobacterium breve metagen in the aspects of scavenging free radicals and relieving oxidative aging. According to the present invention, the oxidative free radical scavenging experiment results show that the bifidobacterium breve NKU BB 1-2 metagen has good oxidative free radical scavenging ability, and has good scavenging ability on hydroxyl free radicals, superoxide anions and DPPH free radicals; meanwhile, through component analysis, it is found that the bifidobacterium breve NKU BB 1-2 metagen contains various antioxidant and anti-aging bioactive substances such as flavonoids, indoles, amino acids, bile acids and ceramides; a cell model experiment verifies that the bifidobacterium breve NKU BB 1-2 metagen can obviously relieve oxidative damage to the cells and improve the oxidation resistance of the cells, so that oxidative aging is relieved.

The invention belongs to the technical field of biological medicine, and discloses a dry blood spot liquid chromatography-mass spectrometry detection method adaptive to 7 metabolites. According to the method, a pH / polarity double-trigger microcapsule solvent carrier system is adopted, high-polarity extraction solvents, medium-polarity extraction solvents and low-polarity extraction solvents are packaged in the pH / polarity double-trigger microcapsule solvent carrier system in a layered mode, the solvents are released in sequence according to local pH and polarity changes in the extraction process, and amino acid, acyl carnitine, organic acid, bile acid, steroid, fatty acid and glycometabolism intermediate products are efficiently extracted respectively. The method disclosed by the invention breaks through the inherent limitation of a traditional static solvent system, solves the problem of unbalanced recovery rate caused by insufficient solvent suitability in dry blood spot extraction of seven metabolites with great polarity span, and remarkably improves the accuracy, reproducibility and coverage range of a DBS-LC-MS / MS platform in synchronous detection of multi-component metabolites; and reliable technical support is provided for newborn inherited metabolic disease screening, endocrine disease diagnosis and drug metabolism research.

This invention belongs to the field of bile acid detection technology, and discloses a sample pretreatment method for determining the content of bile acid subtypes and its application. The pretreatment method includes the following steps: S1, acidifying the sample to be tested with an acidifying agent to a pH of 2-4 to obtain an acidified sample; S2, eluting the acidified sample onto a mixed-mode anion exchange column to obtain an eluent; S3, evaporating the eluent and reconstituted with a rehydration solution to obtain the test sample. The test sample obtained by this pretreatment method can effectively eliminate or compensate for matrix interference when used for targeted analysis of bile acid subtypes by LC-MS / MS, thus effectively improving detection sensitivity.

The invention relates to the technical field of aquaculture feed, and provides a compound feed additive for improving fish sugar utilization rate and promoting growth, the compound feed additive comprises the following raw materials by weight: 0.1-0.14 part of chromium picolinate, 1.5-2.5 parts of vitamin C, 20-40 parts of amylase, 20-40 parts of protease, 10-20 parts of dimethyl-beta-propiothetin, 2-4 parts of bile acid, and 18-22 parts of a carrier. The compound feed additive provided by the invention has the beneficial effects that the blood sugar is regulated, and the sugar metabolism capability of fish bodies is improved; due to the use of the compound feed additive, energy supply caused by protein decomposition is reduced, so that the growth performance of the fishes and the utilization rate of the feed are improved; the low-temperature stress resistance of the fishes is improved, and the breeding negative influence caused by temperature change is reduced; the protein loss is reduced; the feed cost is reduced; and the culture benefit is improved.

The present invention provides means with which bile acids, phenols, indoles and organic acids contained in a sample can be stably preserved without cryopreservation of the sample. A sample preservation solution of the present invention is a sample preservation solution used for analyzing at least one component selected from the group consisting of bile acids, phenols, indoles and organic acids contained in a biological or environmental sample, containing at least the following (A) and (B): (A) condensed phosphate or polyoxyethylene sorbitan alkylate; and (B) guanidinium thiocyanate, Tris-HCl (pH 7 to 9), and EDTA.

The application relates to the technical field of medical detection, in particular to a detection kit for total bile acid and a detection kit for total bile acid. The application adds polyoxyethylene-polyoxypropylene copolymer, Span 40 and oxide in R1, and adds EDTA-Na2 and sodium bicarbonate in R2, so that the stability and precision of reagents are effectively improved, and the situation that a negative value is generated in the detection process is solved.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

A GCPII inhibitor comprising 2-(phosphonomethyl)pentanedioic acid (2-PMPA) conjugated to a bile acid, and its use for treating diseases or conditions associated with elevated GCPII levels, such as inflammatory bowel disease.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The application discloses a compound, a preparation method and a use for preparing a derivatization reagent, and belongs to the field of chemistry. The application claims a compound TMT-mAla-PP with a novel chemical structure and a preparation method and a use thereof. Compared with the same compound TMT-PP or TMT-Pro-PP in the prior art, the derivatization product obtained by using the TMT-mAla-PP provided by the application as a derivatization reagent for performing a derivatization reaction on a bile acid compound has a significantly better mass spectrometry response sensitivity. Therefore, the compound provided by the application can be used for preparing a derivatization reagent for a bile acid compound, and the derivatization reagent can perform derivatization modification on the bile acid compound before mass spectrometry detection of the bile acid compound, so that the detection performance of the mass spectrometry on the bile acid compound is significantly improved.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The invention provides rhizoma alismatis purified polysaccharide as well as a preparation method, an identification method and application thereof, the rhizoma alismatis purified polysaccharide is a functional component with a novel structure in a traditional Chinese medicine rhizoma alismatis water extract obtained by further extraction and purification, the administration efficiency is effectively improved, and the pharmacodynamic substances are clarified; in-vivo and in-vitro experiments show that the polysaccharide can improve the antioxidant capacity of the liver and relieve inflammatory response; synthesis and metabolism of liver bile acid can be adjusted, cholestasis of the liver is relieved, and bile acid circulation is promoted so as to relieve acute liver injury caused by acetaminophen; the effect of promoting the recovery of liver injury patients is obvious; and the compound also can be used as prebiotics to improve the homeostasis of intestinal microorganisms and promote the synthesis of short-chain fatty acids so as to have beneficial effects on the liver.

The present invention addresses the problem of: developing a method capable of noninvasively sampling and analyzing intestinal mucosa bacteria; analyzing the intestinal bacteria, especially intestinal mucosa bacteria on the basis of the method; and developing a therapeutic method for diseases occurring in the intestinal tract for which therapeutic methods have not been established.　The inventors of the present invention have found that bacteria contained in a cotton swab (swab) sample on the feces surface exhibit a bacterial flora composition similar to that of bacteria existing in the intestinal mucosa; and, as a result of analysis based on the finding, have clarified that Adlercreutzia, which has not been reported until now as a mucosa-related bacterium, lives in the large intestinal mucosa layer, produces taurine, which is a strong anti-inflammatory compound, by the action of the bile acid-deconjugating enzyme, and alleviates enteritis, thereby completing the present invention. In other words, the present invention can provide a composition having an anti-inflammatory effect, which includes a bacterium of the genus Adlercreutzia, or a bile acid-deconjugating enzyme that is derived from a bacterium of the genus Adlercreutzia.

The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and / or hepatic bile acid transport (LBAT) inhibitory activity. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases.

Provided is a compound that can be used as an antitumor agent and exhibits improved biocompatibility. The compound according to the present disclosure comprises a bile acid and a polymer chain. The polymer chain is formed from a biocompatible cationic polymer.

The invention discloses application of glucoraphanin to preparation of a product for reducing biological accumulation of perfluorooctane sulfonate, and belongs to the technical field of biological medicine. The occurrence probability of the high PFOS level in the body of a participant frequently eating broccoli is confirmed to be remarkably reduced through population epidemiological experiments, and then the PFOS level in the body of the participant is confirmed to be remarkably reduced after glucoraphanin intervention through clinical RCT random control experiments. The glucoraphanin-intervened serum has the advantages that the glucoraphanin-intervened serum is used as a main body, the metabolic change of steroid, ceramide and bile acid in the glucoraphanin-intervened serum is confirmed to be closely related to the reduction of the PFOS level through lipidomics analysis, and finally, the glucoraphanin is confirmed to be capable of effectively reducing the PFOS in-vivo accumulation and improving the liver injury caused by the PFOS through animal experiments and an AI reverse targeting technology; and the glucoraphanin and the in-vivo metabolite sulforaphane thereof have relatively strong binding capacity with a liver-specific PXR receptor, so that a good technical foundation is laid for research and development of drugs for treating diseases related to PFOS accumulation.

The invention relates to the technical field of biological pharmacy, in particular to a method for extracting bile acid from pig bile, which comprises the following steps: (1) taking the pig bile, adjusting the pH value of the pig bile to be alkaline, heating the pig bile to 80-90 DEG C, stirring at constant temperature for 25-35 minutes, then cooling to room temperature, and adjusting the pH value of the system to be neutral to obtain pretreated pig bile; (2) filtering the pretreated pig bile in the step (1) by using a hyperbranched polymer film, concentrating filtrate under reduced pressure, adding an ethanol solution, heating to reflux, stirring for 25-35 minutes, and then filtering to obtain a crude bile acid product; and (3) adding a hydrochloric acid solution into the crude bile acid product in the step (2), adjusting the pH value to 2-3, centrifuging, filtering, washing and drying the obtained solid, adding ethyl acetate, heating to reflux until the solid is dissolved, cooling to room temperature, stirring for 2-4 hours, recrystallizing, separating and drying to obtain the bile acid. The extraction method is simple, and the extraction purity is high.

The present invention relates to the medical and food use of bile acid derivatives. Specifically, the present invention relates to the use of 3-oxoLCA in reducing oxidative stress and inflammation in pregnant mothers and their offspring. Specifically, the present invention relates to the use of 3-oxoLCA to reverse the effects of oxidative stress on pregnant mothers, in particular, to maintain fetal equal weight, significantly reduce placental and liver oxidative stress in pregnant mothers and the resulting inflammation or dysfunction of the placenta and liver, and to improve the intestinal flora imbalance of pregnant mothers. Further studies have found that 3-oxoLCA has long-term effects, in particular, can significantly reduce the effects of oxidative stress during pregnancy on oxidative stress and inflammation in the liver of offspring.

Provided herein are methods and compositions related to treating or preventing metabolic disorder.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.